Rodríguez-Landa Juan Francisco, Olmos-Vázquez Oscar Jerónimo, Quiñonez-Bailón Carlos Fabrizio, Guillén-Ruiz Gabriel, Limón-Vázquez Ana Karen, Cueto-Escobedo Jonathan, Rivadeneyra-Domínguez Eduardo, Bernal-Morales Blandina
Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa 91190, Veracruz, Mexico.
Facultad de Química Farmacéutica Biológica, Universidad Veracruzana, Xalapa 91000, Veracruz, Mexico.
Metabolites. 2025 May 6;15(5):311. doi: 10.3390/metabo15050311.
: Premenstrual syndrome is characterized by emotional changes, including anxiety and depression symptoms, which may be treated with anxiolytic and antidepressant drugs, as well as estrogen therapy. However, steroidal estrogen therapy is contraindicated for patients with a potential risk of developing estrogen-dependent cancers through interactions with estrogen receptor α (ERα). Alternatively, genistein produces estrogenic effects in animals and humans at dietary dosages that act on the nuclear and membrane ERα, estrogen receptor β (ERβ), and the G-protein-coupled estrogen receptor (GPER). These receptors are likely involved in the anxiety symptoms observed in premenstrual disorders. The objective of this study was to evaluate the effects of genistein and 17β-estradiol on anxiety-like behavior and the plasma concentrations of estradiol and progesterone throughout the ovarian cycle of Wistar rats. : The effect of the administration of 0.09 mg/kg of genistein or 17β-estradiol was evaluated using the elevated plus maze (EPM) test, locomotor activity test (LAT), and light/dark box (LDB) test, as well as by assessing the plasma concentrations of estradiol and progesterone, while considering the ovarian cycle phases. : Higher levels of anxiety-like behavior were detected in the metestrus-diestrus phase compared to the proestrus-estrus phase, which was associated with low concentrations of estradiol. Genistein, similarly to 17β-estradiol, significantly reduced anxiety-like behaviors in the EPM and LDB; however, 17β-estradiol, but not genistein, significantly increased the plasma estradiol concentration. No significant changes were found in locomotor activity or the plasma progesterone concentrations due to the treatments. : These findings suggest that genistein may be useful in the development of alternative therapies to reduce the anxiety associated with low steroid hormone concentrations, which occur in premenstrual syndrome. Genistein could be an alternative to steroidal estrogen therapy to avoid potential side effects due to estradiol or antidepressant treatments, although it still requires medical care.
经前期综合征的特征是情绪变化，包括焦虑和抑郁症状，可使用抗焦虑和抗抑郁药物以及雌激素疗法进行治疗。然而，甾体雌激素疗法对于有通过与雌激素受体α（ERα）相互作用而发展为雌激素依赖性癌症潜在风险的患者是禁忌的。另外，染料木黄酮在动物和人类中以饮食剂量产生雌激素作用，作用于核和膜ERα、雌激素受体β（ERβ）以及G蛋白偶联雌激素受体（GPER）。这些受体可能与经前期疾病中观察到的焦虑症状有关。本研究的目的是评估染料木黄酮和17β-雌二醇对Wistar大鼠整个卵巢周期中焦虑样行为以及雌二醇和孕酮血浆浓度的影响。：使用高架十字迷宫（EPM）试验、运动活动试验（LAT）和明暗箱（LDB）试验，以及通过评估雌二醇和孕酮的血浆浓度，同时考虑卵巢周期阶段，来评估给予0.09mg/kg染料木黄酮或17β-雌二醇的效果。：与发情前期-发情期相比，在间情期-动情后期检测到更高水平的焦虑样行为，这与低浓度的雌二醇有关。染料木黄酮与17β-雌二醇类似，在EPM和LDB中显著降低焦虑样行为；然而，17β-雌二醇而非染料木黄酮显著增加血浆雌二醇浓度。由于治疗，运动活动或血浆孕酮浓度未发现显著变化。：这些发现表明，染料木黄酮可能有助于开发替代疗法，以减少经前期综合征中出现的与低甾体激素浓度相关的焦虑。染料木黄酮可以替代甾体雌激素疗法，以避免由于雌二醇或抗抑郁治疗引起的潜在副作用，尽管它仍然需要医疗护理。
